EyePoint Pharmaceuticals Inc is a US-based specialty pharmaceutical company which is engaged in developing sustained-release drug delivery products and technologies to treat serious, debilitating diseases of the eye that can lead to blindness. The company has developed three sustained-release products for the treatment of back-of-the-eye diseases. The lead product candidate is Durasert which is designed to treat chronic non-infectious uveitis affecting the posterior segment of the eye for three years from a single injection. The company's development program is focused primarily on utilizing two core technology platforms to deliver drugs and biologics to treat chronic diseases.